Daniel Sturm

Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States

PURPOSE: Ruxolitinib cream (Janus kinase [JAK]1/JAK2 inhibitor) was effective and well tolerated in clinical trials of patients with atopic dermatitis (AD). We examined real-world outcomes among patients with moderate AD treated with ruxolitinib cream or systemic therapies. METHO...

Real-World Effect of Ruxolitinib Cream: Decreased Use of Additional Topical Therapies and Limited Escalation to Systemic Treatments

Abstract Introduction Ruxolitinib cream has demonstrated efficacy and safety in patients aged ≥ 2 years with mild to moderate atopic dermatitis (AD) in clinical trials. Early real-world data have demonstrated results consistent with clinical trial observations and have indicated...